Previous And Confirmed Speakers 2019
|
Uwe Gottschalk (Switzerland)
CSO - Lonza Uwe Gottschalk is Chief Technology Officer (CTO) at Lonza Pharma/Biotech since June 2014. Before joining Lonza he served as Group Vice President at Sartorius Stedim Biotech between 2004 and 2014 with a global responsibility for all bioseparation-related process technology. He worked in different capacities for Bayer Health Care from 1991 to 2004, overseeing the process development and manufacturing of biopharmaceutical products such as monoclonal antibodies and other recombinant proteins. |
|
|
Judy Chou (USA)
SVP and Global Head of Biotech - Bayer Pharmaceuticals Experienced Senior Vice President of Pharmaceutical / Technical Operations with a demonstrated history of working in the pharmaceutical industry. Skilled in Biotechnology, Drug Development & Discovery, Manufacturing& Supply Chain, Bioprocess, Analytical & Formulation, and Oncology. Strong leadership professional graduated from Yale University. |
|
|
Alain Bernard (Belgium)
Head of Biotech Process Development - R-PHARM Dr. Alain has over 30 years of experience in biotechnology process development, tech transfer, technology development and integration into process flows, including production of clinical and commercial GMP products. He previously served as Vice-President, Global Portfolio of UCB‘ s technical operations managing the prioritization and governance of the different projects. Prior to that role he was in charge of overseeing process developments for new chemical and new biological entities as well as for lifecycle management of marketed products. He joined UCB in 2006, from Serono where he was Director of Process Development. |
|
|
Kumar Dhanasekharan, Ph.D (USA)
Head of Biologics Development - Amicus Therapeutics Dr. Dhanasekharan is Head of Biologics Development at Amicus Therapeutics responsible for development and scale-up of biologics of early and late phase programs. Previously, he was responsible for process and analytical development at Cook Pharmica, a contract and development organization (CDMO) in Bloomington, Indiana. Prior to that, he was at Genzyme-Sanofi in various leadership roles including process development, process engineering and manufacturing sciences at Genzyme in Framingham, Massachusetts. |
|
|
Jens Vogel (USA)
President & CEO BI Fremont - Boehringer Ingelheim Jens H. Vogel, Ph.D. is President and CEO of Boehringer Ingelheim Fremont Inc. Jens has more than 20 years of experience in all aspects of biopharmaceutical development and manufacturing, through senior leadership roles in process & technology development, GMP manufacturing and global project leadership in the US, Germany and the UK. |
|
|
Dorothee Ambrosius (Germany)
Head of Biologicals Strategy - Boehringer Ingelheim Dorothee joined the leadership team of Boehringer Ingelheim on October 1, 2010 as Senior Vice President, Global Process Science. Her knowledge and over 20 years experience in research and development of Biopharmaceuticals has enabled her to serve as an asset to the organization as she leads the Process Science organization globally. |
|
|
Shawn Barrett (USA)
Associate Scientific Director, Continuous Manufacturing Skill Center, BioPharma Develop - Sanofi Shawn Barrett is the Associate Scientific Director of USP in the Continuous Manufacturing Skill Center at Sanofi in Framingham, MA. He has more than 20 years of experience at various organizations in the biopharmaceutical and biotech industry, including Life Technologies BioProduction, Centocor J&J R&D, Eli Lilly BioRTP, and NRC Biotechnology Research Institute. His bioprocess expertise includes fed batch and perfusion cell culture process development and scale-up, cell culture medium development, bioreactor and facility design, and process control. Shawn currently leads the optimization and intensification of a perfusion platform process for the enablement of integrated continuous manufacturing of protein therapeutics. |
|
|
Eugenio Filippi (Austria)
Head of Manufacturing - Purification - Shire Prior to joining Baxter as Molecular Biology Manager in 2010, Eugenio has worked in a number of roles at IBM, among which as Operations Manager in the Bratislava International Services Center and as IT & Transformation Manager for IBM Austria & Switzerland. In April 2013 Eugenio was appointed Senior Manager Logistics, and since April 2016 he is leading all European Plasma Operations, which include Logistics, Testing (Serological and NAT) and Plasma dispositioning. |
|
|
Zorica Dragic (Switzerland)
Team Head Cell line development - Novartis |
|
|
Frank Agbogbo (USA)
Director of Microbial Bioprocess - Cytovance Biologics Frank has over 16 years of experience in academia and industry. He is currently the Director of Microbial Bioprocess at Cytovance Biologics and he has been with the company since May 2014. Prior to Cytovance, Frank was a Scientist at Novozymes, ICM, Inc., and Mascoma Corporation. He also served as Application Technology Manager at Mascoma Corporation where he contributed to the FDA approval and launch of two commercial products (TransFerm®). His background includes microbial process development, Design of experiments, Process Optimization, Process Characterization and Scale-Up from R&D to Manufacturing (cGMP and non-cGMP). |
|
|
Stefan Schmidt (Germany)
Chief Scientific Officer - Bioatrium As CSO he is directing the department of Bioprocess Technology & Innovation focusing on identifying and implementing new manufacturing approaches and methods. He is heavily involved in the strategic orientation of our CDMO business. Prior to that as Senior Vice President Stefan managed a unit of more than 250 people performing process development and production in11 bioreactor lines with scales from 250L to 3000L both in stainless steel and disposables, delivering drug substance of complex biologics for toxicology studies, clinical trials (PI-III) and commercial supply. |
|
|
Hitto Kaufmann (Germany)
Global Vice President Biopharmaceutics Development and Platform Innovation - Sanofi Hitto Kaufmann is currently Global Vice President BioPharmaceutics Development & Platform Innovation within Sanofi R&D. BioPharmaceutics Development is a strong science-based organization within Sanofi R&D operations that develops manufacturing processes for protein, antibody and viral vector drug substance and drug product and manufactures GMP materials for clinical studies. Previously he was heading Technology and Development within the Biologics platform of Sanofi Industrial Affairs. |
|
|
Hubert Chen (USA)
Chief Medical Officer - Pfenex Hubert C. Chen, M.D. has served as Pfenex’s Chief Medical & Scientific Officer since May 2017. He previously served as the Company’s Chief Medical Officer from November 2014 to May 2017. From 2012 to 2014, Dr. Chen served as Vice President, Clinical Development of Aileron Therapeutics, a biopharmaceutical company developing and advancing drugs using novel peptide-stabilizing technologies. |
|
|
Martin Mueller (USA)
Director, Biotech Development - MSD Martin Mueller, Ph.D., Biotech Engineer, started his career at a Biotech startup in Berlin, before being a GLP study director at the globally acting CRO “RCC” (today: Harlan Labs). With this experience he joined Schering-Plough’s Biotech division for building up the Global GMP Labs. In 2012, Martin accepted a leading position within MSD’s BioProcess Division in New Jersey, U.S.. Today he manages a local MSD-team in Switzerland and international teams for developing MSD’s top biologics pipeline. |
|
|
|
|
Patrick Sagmeister (Austria)
CTO - Exputec Patrick is Chief Technology Officer of EXPUTEC with responsibility for scientific developments, technical innovations and business development. Patrick joined EXPUTEC in 2013. He studied technical chemistry in Graz and Vienna, Austria. Patrick received his PhD in biochemical engineering from the Technical University of Vienna. His research profile includes bioprocess development, mathematical modelling of biochemical systems and applied statistics. |
|
|
Michael Backhaus (Austria)
Lead of Manufacturing Intelligence IT Europe/Asia - Shire Michael Backhaus is an experienced IT professional with a background of software development and management in the scientific research, healthcare and pharmaceutical domains. As part of the technical operations network in Shire, a company with a total revenue of US$11.4bn, he is supporting the implementation of automated IT solutions to optimize reporting activities, improve process control, and increase product value. |
|
|
Xavier Derouck (Belgium)
Senior Manager, Global Operations Procurement - GlaxoSmithKline Xavier Derouck is Global Sourcing Senior Manager in charge of Single-Use Systems for GSK Vaccines. Xavier is also Subject Matter Expert for Suppliers Relationship Management. He has over 15 years’ experience in the procurement and supply chain, covering the automotive, chemical and pharma industry. Before he joined GSK, Xavier was Procurement Site Manager for the Baxter Medical Products major manufacturing site in EMEA. |
|
|
Dirk Voelkel (Sweden)
Chief Technology Officer - Innovation and Analytics - GE Healthcare Life Science Dr. Dirk Voelkel, Chief Technology Officer, Innovation and Analytics Life Science, joined GE Healthcare Life Sciences in July 2012. In his role he manages the R&D and technology portfolio of GE Life Sciences and the Life Science innovation activities. Previously, Dr. Voelkel headed the Research and Technology department in Roche Diagnostics Diabetes Care Mannheim, developing new technologies to address the needs of diabetic patients world wide. In prior roles he was a technology scout in the San Francisco bay area and a project leader in R&D, developing systems for glucose monitoring. |
|
|
Thomas Kretschmann (Germany)
Field Application Specialist - Cytena GmbH |
|
|
Romain Dabre (Germany)
Product Manager Process Business - Tosoh Bioscience GmbH |
|
|
Ralph Daumke (Switzerland)
Market Manager Biologics - FILTROX Group |
|
|
Hans J Johansson (Sweden)
Application Manager - Purolite Hans Johansson has over 30 years of experience in the biotech business, having spent 25 years with Pharmacia/Amersham/GE Healthcare. He holds more than ten patents in the area of resin design and large-scale protein purification. Hans leads the Applications group in Purolite Life Sciences - Agarose. |
|
|
Kai Touw (The Netherlands)
Process Development Consultant - Sartorius Stedim Biotech |
|
|
Frank Abbato (USA)
Principal - Enguition (on behalf of Bio-G) |
|
|
Alessandro Butte (Switzerland)
Lecturer and Senior Reseacher - ETH Zurich Alessandro Butté received his Ph.D. in Chemical Engineering in 2000 from ETH Zurich. After a two-year post-doc at the Georgia Institute of Technology, he join the group of Prof. Morbidelli at ETH Zurich and completed his habilitation in 2008. During this period, his research activities focused on polymer engineering, production of nano-materials for protein purification (monoliths by reactive-gelation) and chromatography purifications of peptides, proteins and Mabs. In 2008, he joined Lonza as leader for downstream activities in the sectors small molecules and peptides and as project manager. |
|
|
Ulrich Rümenapp (Germany)
Head of Launch Preparation - Bayer Dr. Rümenapp is based in Wuppertal, Germany and working within the Biological Development organization of Bayer AG, where he is responsible for the transfer of Bayer’s pipeline candidates (antibodies and antibody-drug-conjugates) to external manufacturing partners and regulatory submission and launch preparations. Dr. Rümenapp was Head of Biotech Projects in Product Supply Biotech at Bayer, where he was responsible for contract manufacturing partnerships in the field of biotechnological drug substances and drug products and interdisciplinary project management with the goal to ensure market supply. |
|
|
Alison Arnold (United Kingdom)
Head of Fermentation Development - Ingenza |
|
|
Markus Haindl (Germany)
Director Development Analytics - Roche |
|
|
Georgios Kararigas (Germany)
DZHK Professor - Charite University Hospital Berlin Since November 2015, Georgios Kararigas is a DZHK Professor of Translational Gender Research with a focus on heart failure at the Institute of Gender in Medicine of the Charité University Hospital in Berlin. His primary research interests include mechanisms of sex differences in cardiovascular (patho) physiology, hormonal effects in the heart, gene expression and regulation. In particular, he focuses on the analysis of heart‑specific regulatory functions of oestrogen using a combination of computational and genome‑wide methods, in vitro and in vivo models, in animals and human‑derived material, and the effects of sex on those. His goal is the development of novel therapies for heart failure. |
|
